


AMENDMENTS TO THE CLAIMS

1-10. (Cancelled).

11. (Currently Amended) A method for ~~preventing~~ reducing or treating hearing impairment in a subject undergoing treatment with ~~an ototoxic chemotherapeutic drug selected from an aminoglycoside antibiotic, a platinum-containing antineoplastic agent, a quinine-like compound or an ototoxic diuretic drug~~, comprising administering to the subject in need of such treatment a therapeutically effective amount of a compound represented by formula I:



Formula I

wherein

R₁ and R₂ taken together form a substituted or unsubstituted heterocyclyl ring having 4 to 8

members ~~R₁ and R₂, independently for each occurrence, represent alkenyl, alkynyl, alkylthio, imine, amide, cyano, isocyano, carbonyl, carboxyl, carboxamide, alkylsulfonyl, arylsulfonyl, ketone, aldehyde, ester, heteroalkyl, nitrile, amidine, acetal, ketal, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aziridine, carbamate, imide, urea, or thiourea; and~~

~~R₃ is selected from hydrogen, and alkyl, alkenyl, alkynyl, alkylthio, imine, amide, cyano, isocyano, carbonyl, carboxyl, carboxamide, alkylsulfonyl, arylsulfonyl, ketone, aldehyde, ester, heteroalkyl, nitrile, amidine, acetal, ketal, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aziridine, carbamate, imide, urea, or thiourea; or~~

~~R₁ and R₂ taken together form a substituted or unsubstituted heteroaryl or heterocyclyl ring having 4 to 8 members; or~~

~~R₂ and R₃ taken together form a substituted or unsubstituted heteroaryl or heterocyclyl ring having 4 to 8 members.~~

12. (Cancelled).

13. (Currently Amended) The method of claim 11, wherein said compound is administered prior to, simultaneously with, or subsequent to administration of said platinum-containing antineoplastic agent~~tototoxic chemotherapeutic drug~~.

14. (Currently Amended) The method of claim 11, wherein a therapeutically effective amount of the compound is administered with each dose of platinum-containing antineoplastic agent~~tototoxic chemotherapeutic agent~~, at specified intervals throughout the treatment course, or at the beginning of the treatment course.

15. (Currently Amended) The method of claim 11, wherein the compound is administered between 72 hours before and 36 hours after treatment with said platinum-containing antineoplastic agent~~tototoxic chemotherapeutic drug~~.

16. (Cancelled).

17. (Currently Amended) The method of claim 11, wherein the ~~drug is a~~ platinum-containing antineoplastic agent is selected from cis-diaminedichloroplatinum(II) (cisplatin), trans-diaminedichloroplatinum(II), cis-diamine-diaquaplatinum(II)-ion, chloro(diethylenetriamine)-platinum(II) chloride, dichloro(ethylene-diamine)-platinum(II), diamine(1,1-cyclobutanedi-carboxylato)-platinum(II), spiroplatin, dichlorotrans-dihydroxybisopropylamine platinum IV (iproplatin), diamine(2-ethylmalonato)-platinum(II), ethylenediamine-malonatoplatinum(II), aqua(1,2-diaminocyclohexane)-sulfatoplatinum(II), (1,2-diaminocyclohexane)malonato-platinum(II), (4-carboxyphthalato)(1,2-diaminocyclohexane)-platinum(II), (1,2-diaminocyclohexane)-(isocitrato)platinum(II), (1,2-diaminocyclohexane)-cis(pyruvato)platinum(II), ~~or~~ and (1,2-diaminocyclohexane)-oxalatoplatinum(II).

Application No. 10/712,849
Amendment dated September 9, 2008
After Final Office Action of May 12, 2008

Docket No.: SEPR-P01-056

18-30. (Cancelled).